You are here

hemophilia A

Spark offers a glimpse of efficacy in first two hemophilia A gene therapy patients

Spark offers a glimpse of efficacy in first two hemophilia A gene therapy patients

Endpoints

Spark Therapeutics

Flag link:

Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger

Roche’s hemophilia drug slashes bleeding rate, boosting blockbuster projections — but doubts on safety linger

Endpoints

clinical trials

Flag link:

Shire writes off a shot at long-acting hemophilia drug after small study flops

Shire writes off a shot at long-acting hemophilia drug after small study flops

Endpoints

Xenetic Biosciences

clinical trials

Flag link:

Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal

Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal

Endpoints

Sangamo BioSciences

Flag link:

Roche claims that its interim update on hemophilia A drug is positive. But it’s hard to gauge.

Roche claims that its interim update on hemophilia A drug is positive. But it’s hard to gauge.

Endpoints

Flag link:

Roche gears up to enter loaded hemophilia A drug market

Roche gears up to enter loaded hemophilia A drug market

Medical Marketing and Media

Flag link:

Roche Finds Safe Haven In Emicizumab

Roche Finds Safe Haven In Emicizumab

Seeking Alpha

Flag link:

Roche readies a hunt for marketing OK on hemophilia blockbuster hopeful emicizumab after PhIII success

Roche readies a hunt for marketing OK on hemophilia blockbuster hopeful emicizumab after PhIII success

Endpoints

Flag link:

Hey, wait a second. What about Roche’s PhIII hemophilia A drug?

Hey, wait a second. What about Roche’s PhIII hemophilia A drug?

Endpoints

Flag link:

Germany's Bayer wins U.S. FDA approval for hemophilia A therapy

Germany's Bayer wins U.S. FDA approval for hemophilia A therapy

Yahoo/Reuters

Flag link:

5 Reasons Roche Thinks It Can Outclass the Competition

5 Reasons Roche Thinks It Can Outclass the Competition

Motley Fool

dry macular degeneration

Flag link:

Roche haemophilia drug wins fast-track FDA designation

Roche haemophilia drug wins fast-track FDA designation

Yahoo/Reuters

Flag link:

Playing defense, Baxalta makes its case for a new hemophilia drug

Playing defense, Baxalta makes its case for a new hemophilia drug

Fierce Biotech

Flag link:

3 Reasons That Biogen's Shares Could Rise

3 Reasons That Biogen's Shares Could Rise

Investopedia

Alzheimer's disease

Flag link:

Biogen Idec quietly carves out a leading role in developing gene therapy for hemophilia

Biogen Idec quietly carves out a leading role in developing gene therapy for hemophilia

Fierce Biotech

Flag link:

FDA clears Baxter hemophilia A treatment

FDA clears Baxter hemophilia A treatment

Seeking Alpha

Baxter International

Flag link:

Long-acting version of Baxter's hemophilia drug succeeds in study

Long-acting version of Baxter's hemophilia drug succeeds in study

Yahoo/Reuters

Baxter International

Flag link:

U.S. FDA approves Biogen's hemophilia A drug Eloctate

U.S. FDA approves Biogen's hemophilia A drug Eloctate

Yahoo/Reuters

Flag link:

FDA approves Biogen's hemophilia A drug Eloctate

FDA approves Biogen's hemophilia A drug Eloctate

Yahoo/Reuters

Flag link:

Biogen's blood disorder drug succeeds in late-stage trial

Biogen's blood disorder drug succeeds in late-stage trial

Yahoo/Reuters

Flag link: